Pacific Biosciences of California, Inc.
PACB
$1.37
-$0.01-0.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.07% | 13.82% | -3.82% | 10.42% | -4.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.07% | 13.82% | -3.82% | 10.42% | -4.27% |
| Cost of Revenue | -21.44% | 28.52% | -16.74% | -5.95% | 14.99% |
| Gross Profit | 92.05% | -44.66% | 22.37% | 55.70% | -44.22% |
| SG&A Expenses | -22.44% | -36.21% | -28.91% | -21.15% | -8.19% |
| Depreciation & Amortization | -99.72% | -85.17% | -85.17% | -85.17% | 5,249.50% |
| Other Operating Expenses | -- | 318.64% | -- | -- | -- |
| Total Operating Expenses | -83.94% | -18.58% | -24.91% | -28.10% | 290.70% |
| Operating Income | 91.16% | 32.80% | 38.32% | 45.09% | -431.28% |
| Income Before Tax | 98.10% | -1,594.94% | 38.05% | 75.83% | -445.39% |
| Income Tax Expenses | 160.93% | -36.08% | -- | -- | -- |
| Earnings from Continuing Operations | 98.06% | -1,802.70% | 37.42% | 75.81% | -445.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 98.06% | -1,802.70% | 37.42% | 75.81% | -445.01% |
| EBIT | 91.16% | 32.80% | 38.32% | 45.09% | -431.28% |
| EBITDA | 42.68% | 29.33% | 31.89% | 42.28% | 14.33% |
| EPS Basic | 98.11% | -1,691.67% | 43.24% | 78.04% | -394.93% |
| Normalized Basic EPS | 91.40% | 42.05% | 42.74% | 52.56% | -376.47% |
| EPS Diluted | 97.92% | -1,730.49% | 41.57% | 78.13% | -396.55% |
| Normalized Diluted EPS | 91.40% | 37.16% | 42.74% | 52.56% | -376.47% |
| Average Basic Shares Outstanding | 3.02% | 6.68% | 10.23% | 10.20% | 10.12% |
| Average Diluted Shares Outstanding | 3.02% | -1.62% | 10.23% | 10.20% | 10.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |